Interferon a and γ in the serum of primary bone tumors patients

Serum levels of interferon γ (IF-γ) in healthy donors and in patients with benign bone neoplasms were significantly high comparing to borderline and malignant bone tumors. No reliable distinguishes were found between serum levels of IF-α in patients with benign, borderline and malignant bone tumors. Invert correlation was shown between age and serum level of IF-α in healthy donors, on the contrary no correlations were observed between age and serum levels of IF-γ and of IF-α in patients with bone neoplasms. and also serum IF-γ and IF-α levels in patients with bone sarcomas are not dependant on the tumors histology and on the size of primary bone tumors. No correlations were found in the levels of IF-α and IF-γ in patients with localized and metastatic tumor processes. direct correlation was found between IF-α and IF-γ serum levels in patients with malignant bone tumors in condition of maximal IF-concentrations in blood serum and advanced tumors.

interferon α, interferon γ, blood serum, bone tumors

1. Baron S., Hernandez J., Bekisz J. et al. Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro. J. Interferon Cytokine Res. 2007, v. 27, No. 2, p. 157-163.

2. Boye K., Andersen K., Tveito S. et al. Interferon-gamma-induced sup-pression of S100A4 transcription is mediated by the class II transactivator. Tumour Biol. 2007, v. 28, No. 1, p. 27-35.

3. Gimeno R., Lee C.K., Schindler C., Levy D.E. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol. Cell Biol. 2005, v. 13, p. 5456-5465.

4. Inaba H., Glibetic M., Buck S. et al. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by upregulating Fas receptors and caspase-8. Pediatr. Blood Cancer. 2004, v. 43, No. 7, p. 729-736.

5. Meda L., Gasperini S., Ceska M., Cassatella M.A. Modulation of proinflammatory cytokine release from human polymorphonuclear leukocytes by gamma interferon. Cell Immunol. 1994, v. 157, No. 2, p. 448-461.

6. Nishimura M., Yuasa K., Mori K. et al. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact. J. Orthop. Res. 2005, v. 23, No. 5, p. 979-987.

7. Pedersen K.B., Andersen K., Fodstad O., Maelandsmo G.M. Sensitization of interferon-gamma induced apoptosis in human osteosarcom a cells by extracellular S100A4. BMC Cancer. 2004, No. 4, p. 52.

8. Salvi D., Kiyokawa H., Colamonici O.R. et al. Identification of an immunogenic EWS-FLI1-derived HLA-DR-restricted T helper cell epitope. Pediatr. Hematol. Oncol. 2005, v. 22, No. 4, p. 297-308.

9. Sandoval R., Xue J., Pilkinton M. et al. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J. Biol. Chem. 2004, v. 279, No. 31, p. 32275-32280.

10. Sato T., Onai N., Yoshihara H. et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat. Med. 2009, v. 15, No. 6, p. 696-700.

11. Strander H. Interferons and osteosarcoma. Cytokine Growth Factor Rev. 2007, v. 18, No. 5-6, p. 373-380.

12. Wenner C.A., Gueler M.L., Macatonia S.E. et al. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J. Immunol. 1996, v. 156, No. 4, p. 1442-1447.

13. Yamano Y., Araya N., Sato T. et al. Abnormally high levels of virus-infected IFN-gamma+ CCR4+ CD4+ CD25+ T cells in a retrovirus-associated neuroinflammatory disorder. PLoS One. 2009, v. 4, No. 8, E. 6517.

14. Young H.A., Hardy K.J. Role of interferon-gamma in immune cell regulation. J. Leukoc. Biol. 1995, v. 58, No. 4, p. 373-381